黑料吃瓜群网

Medical data and technology company has signed an agreement with (JHC) in Western Australia to incorporate a paid pilot of the HeraCARE digital pregnancy monitoring platform.

HeraMED provides pregnant mothers with foetal heart rate monitors (the HeraBEAT), allowing expectant mothers to monitor their baby鈥檚 heart rate at home and doctors to remotely monitor the mother and child, improving the experience of telehealth consultations and allowing for better peace of mind during pregnancy. One hundred expectant mothers are involved in the pilot ahead of an anticipated commercial rollout for the use of HeraMED鈥檚 technology as a standard service, to be offered to all pregnant mothers under JHC鈥檚 care.

A clinical study conducted by JHC in 2020 validated the clinical and functional aspects of the HeraBEAT device, with results revealing impressive accuracy when compared with the industry gold standard cardiotocography (CTG) machine. Foetal heart rate (FHR) was detected on 100% of occasions by clinicians and, importantly, the FHR was detected on 100% of occasions by the expectant mothers when using the device without assistance.

JHC is introducing the HeraCARE platform as an innovative model for remote monitoring and care management for pregnant women, allowing the HeraBEAT device and foetal heart rate data to be used in telehealth consultations.

HeraMED CEO and co-founder David Groberman said, 鈥淲e are delighted to have reached this agreement with JHC as it represents a significant achievement in our commercialisation strategy. Representing the first agreement for the full-blown HeraCARE platform, on a technology-as-a-service basis, it is in line with our commercialisation strategy and is expected to underpin further awareness of our technology amongst global healthcare providers.

鈥淛HC is part of Australia鈥檚 largest private hospital operator, Ramsay Health Care Group, and is well regarded as an early adopter of new technologies in obstetrics,鈥� Groberman continued. 鈥淚t is particularly pleasing that JHC have adopted HeraMED鈥檚 innovative technology as it forms part of their strategic plan to become market leaders in adopting innovative care models based on digital health, home-based remote monitoring. We are confident that this partnership will underpin further opportunities with health providers in Australia and globally,鈥� he said.

JHC CEO Dr Amanda Ling said, 鈥淲e are delighted to have reached this agreement with HeraMED and we look forward to being able to incorporate the HeraCARE platform into our remote monitoring and care management programs for pregnant women. At JHC we are continually evaluating and adopting new technology that will improve patient care, and this agreement is a demonstration of that strategy at work,鈥� she said.